Effects of Early IL-17A Neutralization on Disease Induction in a Primate Model of Experimental Autoimmune Encephalomyelitis by Kap, Yolanda S. et al.
ORIGINAL ARTICLE
Effects of Early IL-17A Neutralization on Disease
Induction in a Primate Model of Experimental
Autoimmune Encephalomyelitis
Yolanda S. Kap & S. Anwar Jagessar & Nikki van Driel &
Erwin Blezer & Jan Bauer & Marjan van Meurs &
Paul Smith & Jon D. Laman & Bert A. ‘t Hart
Received: 30 June 2010 /Accepted: 28 July 2010 /Published online: 12 August 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract We report on the effect of antibody-mediated
neutralization of interleukin (IL)-17A in a non-human
primate experimental autoimmune encephalomyelitis
(EAE) model induced with recombinant human myelin
oligodendrocyte glycoprotein (rhMOG). We tested a
human-anti-human IL-17A-antibody in two doses (3 and
30 mg/kg) against placebo (PBS). The treatment was started
1 day before EAE induction and continued throughout the
experiment. Although all monkeys developed clinically
evident EAE, the onset of neurological signs was delayed in
some monkeys from both treatment groups. Total CNS
lesion volumes, demyelination, or inflammation did not
differ between the different groups. Immune profiling
revealed an altered distribution of IL-17A producing cells in
the lymphoid organs of antibody-treated monkeys. Compara-
ble numbers of IL-17A producing cells were observed in the
brain. RhMOG-induced T cell proliferation in the lymph
nodes was slightly reduced after anti-IL-17A antibody
treatment. To summarize, we found that anti-IL-17A antibody
as a single treatment from disease induction effects a trend
towards delayed neurological disease progression in the
marmoset EAE model, although the effect did not reach
statistical significance. This suggests a role of IL-17A in late
stage disease in the marmoset EAE model, but IL-17A may
not be the dominant pathogenic cytokine.
Keywords Th17.IL-23.Antibody therapy.
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Introduction
Multiple sclerosis (MS) is a progressive neurological
disease of unknown origin characterized by the progressive
accumulation of inflammation and degeneration in the grey
and white matter of the central nervous system (CNS). The
accumulation of injury involves a combined cellular and
humoral autoimmune attack on the protective myelin
sheaths around axons leading to disturbed saltatory pulse
conduction (Compston and Coles 2008; Sospedra and
Martin 2005). This immunopathogenic process is modeled
in the experimental autoimmune encephalomyelitis (EAE)
model, an experimental disease induced in genetically
susceptible laboratory animals including mice, rats, guinea
pigs, and monkeys. The EAE model in common marmo-
sets,asmall-sizedneotropicalprimate,combinesaremarkable
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DOI 10.1007/s11481-010-9238-3clinical and neuropathological similarity with MS and a high
genetic and immunological proximity to humans ('t Hart and
Massacesi 2009). The model is therefore exquisitely suitable
for translational research into immunopathogenic mecha-
nisms and the efficacy evaluation of therapeutic antibodies,
which because of their high target specificity do not cross-
react with lower species. The marmoset EAE model thus
forms a bridge narrowing the gap between EAE models and
MS ('t Hart et al. 2004; Kap et al. 2010).
Research conducted in the past years has shown that the
100% disease incidence and variable progression rate of
neurological deficit is associated with the mobilization of
highly reactive T cells present in the normal repertoire with
variable specificities for myelin oligodendrocyte glycopro-
tein (MOG) (Jagessar et al. 2010; Kap et al. 2008). Whereas
disease induction could be mapped to the Caja-
DRB1*W1201 restricted activation of T helper (Th)1 cells
specific for MOG24–36 (Brok et al. 2000), the rate of disease
progression appeared to be regulated by natural killer-like T
cells specific for MOG34–56 (Jagessar et al. 2010; Kap et al.
2008). Further research confirmed that this T cell subset is
capable to induce clinical signs and pathology in the CNS
white and grey matter without the support of innate antigen
receptor ligands in the inoculum or autoantibodies against
rhMOG or the inducing peptides (Jagessar et al. 2010).
These data led to the hypothesis that MOG34–56-specific T
cells have a central pathogenic role in the regulation of
disease progression in the marmoset EAE model.
The most obvious immunological characteristics of
MOG34-56-specific T cell lines generated from EAE-
affected monkeys were specific cytolytic activity towards
MOG34–56-pulsed target cells and production of IL-17A
(Jagessar et al. 2010; Kap et al. 2008). However, typical
Th1 cell-derived cytokines, such as interferon (IFN)-γ or
tumor necrosis factor alpha (TNF-α), that are abundantly
produced by the MOG24–36-specific Th1 cells involved in
EAE initiation (Brok et al. 2000) were not produced by
MOG34–56-specific T cells (Jagessar et al. 2010). This may
well be due to the fact that for the activation of
encephalitogenic Th1 cells in mice as well as in marmosets
strong bacterial adjuvants are needed, i.e. complete
Freund's adjuvant (CFA) (Billiau and Matthys 2001). By
contrast, our data in the marmoset EAE model demonstrates
that encephalitogenic T cells specific for MOG34–56 can
also be activated by immunization with MOG34–56 in
incomplete Freund's adjuvant (IFA) (Jagessar et al. 2010).
These observations prompted us to test whether
antibody-mediated neutralization of IL-17A modulates
disease progression in the EAE model in marmosets,
elicited by a single immunization with recombinant protein
of the extracellular domain of human MOG (MOG1–125)i n
CFA. The most prevalent disease course in this model is
clinically characterized by the sudden appearance of
progressively accumulating motor defects after an episode
of variable length, during which MRI-detectable lesions do
not lead to evident neurological symptoms (Brok et al.
2000; Kap et al. 2008). A typical relapsing-remitting
disease course is only occasionally observed. Our previous
studies have revealed that intervention with an antibody
against the shared p40 subunit of IL-12 and IL-23 has a
clear beneficial effect in the rhMOG-induced EAE model ('t
Hart et al. 2005b; Brok et al. 2002). This supports an
important pathogenic role of IL-12 and IL-23, which may
be exerted via the inhibition of IL-17A production, as IL-23
promotes IL-17A production (Langrish et al. 2005).
Here,wereport that prophylactic treatmentwith anti-IL-17A
monoclonal antibody (mAb) at doses achieving plasmathrough
levels above 1 μg/ml induced a moderate delay of EAE onset.
These data indicate that IL-17A is only one of several cytokines
driving progression of the marmoset EAE model to clinically
evident neuroinflammatory disease; absence of IL-17A being
possibly compensated by Th1 cytokines that are abundantly
produced in the rhMOG/CFA model
Material and methods
Animals
The common marmoset monkeys used in this study were
randomly selected from the outbred colony kept at
the Biomedical Primate Research Centre (Rijswijk, The
Netherlands) under conventional and not SPF conditions.
Animals were only included after a complete physical,
hematological, and biochemical check-up had been per-
formed. During the study, monkeys were pair-housed in
spacious cages and remained under intensive veterinary care.
The daily diet consisted of commercial food pellets for New
World monkeys (Special Diet Services, Witham, Essex,
UK), supplemented with rice, raisins, peanuts, marshmal-
lows, biscuits, fresh fruit, grasshoppers, and maggots.
Drinking water was provided ad libitum. In accordance with
the Dutch law on animal experimentation, all study protocols
and experimental procedures have been reviewed and
approved by the Institute's Ethics Committee.
The study comprised 22 male and two female monkeys,
M05011 and M04049. The average age of the monkeys was
33±16 months, which is adult age for marmosets. The
average body weight was 377±35 g.
RhMOG-induced EAE
EAE was induced by immunization with a recombinant
protein encompassing the extracellular domain of human
MOG residues 1–125, which was produced in Escherichia
coli and purified as previously described (Kerlero de Rosbo
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300 μl phosphate buffered saline (PBS) emulsified with
300 μl CFA containing mycobacterium butyricum (Difco
Laboratories, Detroit, MI), was injected at four locations
into the dorsal skin under ketamin anesthesia (40 mg/kg;
AST Pharma, Oudewater, The Netherlands).
Clinical signs were scored daily by two independent
observers using a previously documented semi-
quantitative scale ('t Hart et al. 2008): 0=no evident
clinical signs; 0.5=apathy, loss of appetite, altered
walking pattern without ataxia; 1=lethargy, anorexia, tail
paralysis, tremor; 2=ataxia, optic disease; 2.25=monopa-
resis; 2.5=paraparesis, sensory loss; 3=para- or hemi-
plegia. For ethical reasons monkeys were sacrificed
before or once complete paralysis of hind limbs (score
≥3.0) was observed, or at the pre-determined endpoint of
the study (post-sensitization day (psd) 113). Body weight
measurements of conscious monkeys, which is used a
surrogate disease marker, were performed three times
per week.
Monkeys selected for necropsy were first deeply sedated
by intramuscular injection of ketamin (50 mg/kg) and
subsequently euthanised by infusion of pento-barbital
sodium (Euthesate®; Apharmo, Duiven, The Netherlands).
Reactivity and dosing regimen of anti-IL-17A mAb
The test substance was produced by UCB Celltech (UK)
as a humanized IgG4κ mAb specific for human IL-17A,
coded as 497.g2. The antibody has been extensively
characterized in vitro in terms of bioassay, affinity for
IL-17A, and cross-reactivity against marmoset IL-17A.
T h ea f f i n i t yo ft h ea n t i b o d yw i t hm a r m o s e tI L - 1 7 Ai s
twofold lower than with hum a nI L - 1 7 Aw h e na s s e s s e d
by Biacore and fourfold less potent in a bioassay
compared with humans.
The animals were subcutaneously injected once a
week starting 1 day before immunization until the pre-
determined end of the study at day 113. Animals were
randomly assigned to three experimental groups. Eight
animals received 3 mg/ml/kg anti-IL-17A mAb diluted in
PBS, eight animals were injected with 30 mg/ml/kg anti-
IL-17A mAb diluted in PBS, and eight control animals
received sterile PBS (1 ml/kg) as placebo treatment. All
animals received the same volume per kg body weight.
One monkey (M04063) in the 30 mg/kg antibody dose
group succumbed at psd 69 unexpectedly without prior
signs of EAE and was therefore excluded from further
analyses. Autopsy revealed that the cause of death was
not related to the test substance or EAE, but to
perforation of the gastro-intestinal tract by plant material,
possibly originating from the branches used for cage
enrichment.
Blood sampling and plasma levels of anti-IL-17A mAb
Venous blood was collected into heparinized vacutainers
(Greiner, Sölingen, Germany) under ketamin anesthesia
(40 mg/kg; AST Pharma, Oudewater, The Netherlands) at
psd 0, 6, 34, 62, and at necropsy.
After centrifugation plasma was collected and stored
frozen at −20°C until analysis of test substance levels was
performed. Test substance plasma levels were determined
by ELISA. Microtitre plates were coated with human IL-
17A (R&D Systems, Minneapolis, MN) at 0.5 μg/mL in
PBS overnight, blocked with PBS/1% BSA, glazed with
PBS/5% lactose/0.1% BSA, dried, sealed in foil pouches,
and stored at 2–8°C. The standard curve was prepared by
making serial doubling dilutions of the 497.g2 top standard
(starting at 200 ng/mL) in PBS/1% BSA/1% BGG/1%
human plasma. 50 μL of each standard, interassay control
(IAC), and sample (diluted at least 1/100) were added to the
appropriate wells containing 50 μL PBS/1% BSA/1%
BGG. The IAC concentrations were nominally 80, 20, and
8 ng/mL. Standards, IAC, and samples were tested in
duplicate. The plate was covered and incubated with agitation
atRTfor2h.TheplatewaswashedwithPBS/0.1%Tween-20
four times and incubated with goat anti-human Kappa-HRP
conjugate (1/10,000) in PBS/1% BSA/1% BGG at RT for
30 min. The plate was washed again with PBS/0.1% Tween-
20 four times and incubated with 100 μL Tetramethyl
benzidine substrate for 10 min. The reaction was stopped
with 50 μL/well of 2.5 M H2SO4 and measured at 450 nm
(and 630 nm as a reference).
Magnetic resonance images
Post-mortem magnetic resonance images (MRI) of one
brain hemisphere were recorded to assess differences in
the CNS lesion load between treated and control
monkeys (Blezer et al. 2007). Half of the brain collected
at necropsy was fixed in 4% buffered formalin and
transferred into buffered saline containing sodium azide
after two weeks.
MRI experiments were performed on a 9.4 T horizontal
bore MRI scanner (Varian, Palo Alto, CA). The formalin-
fixed brains were submerged in a non-magnetic oil
(Fomblin; perfluorinated polyether, Solvay Solexis, Weesp,
The Netherlands) to prevent unwanted susceptibility
artifacts.
The following quantitative images were obtained (field
of view=2.5×2.5 cm
2, matrix=256×256, slice thickness=
0.75 mm, number of slices=41, number of experiments=2);
– T2 maps, which were calculated from the images
obtained of a multi echo sequence using the following
parameters: repetition time=4,000 ms, echo spacing=
J Neuroimmune Pharmacol (2011) 6:341–353 34314.75 ms, echo train length=4. T2 maps were the result
of a mono-exponential fit of the MRI signal intensities
as a function of TE. The T2-weighted images with TE
of 14.75 ms were used for region of interest (ROI)
analyses.
– Magnetization transfer ratio (MTR) maps were calcu-
lated from two T1-weighted spin echo images with
and without a magnetization transfer-saturation pulse,
with MTR=100*[(Munsaturated-Msaturated)/Munsa-
turated]. Repetition time=1675 ms; echo time=
23 ms; MT-pulse: 8.19 ms Gaussian-shaped pulse,
nominal flip angle 1,000, offset −9.4 kHz.
ROI were defined using the free available medical
image processing, analysis and visualization (MIPAV
version 4.3.0, National Institutes of Health, Bethesda,
MD) package. ROI of lesions, defined as areas with
abnormal increased signal intensities, were automatically
outlined in all T2-weighted images containing white
matter structures using the level-set method of MIPAV.
Volumes, T2, and MTR values were calculated from
these ROI.
Histology and immunohistochemistry
Frozen and fixed tissues were processed for histological
and immunohistochemical techniques as previously
described ('t Hart et al. 1998; Laman et al. 1998).
Demyelination was visualized by staining myelin and
myelin degradation products with Klüver Barrera method
(Luxol Fast Blue with Periodic Acid-Schiff). Inflamma-
tion was visualized by staining infiltrating cells with
hematoxylin and eosin. Of each animal eight sections,
approximately 6 cm
2 in total, were analyzed.
Snap-frozen sections of the brain, spleen, and axillary
(ALN), inguinal (ILN), and cervical lymph nodes (CLN)
were used to determine the number of IL-17A-producing
cells. Sections of 6 μm were thaw mounted on gelatin/
chrome alum coated glass slides and stored overnight in
humidified atmosphere. Next day, sections were air-dried
for 1 h at room temperature. Within 2 weeks sections
were fixed at room temperature in fresh acetone contain-
ing 0.02% H2O2. After air-drying, sections were washed
with PBS containing 0.05% Tween-20 (Sigma-Aldrich
Chemie, Zwijndrecht, The Netherlands) and incubated
with 1% blocking reagent (TSA HRP kit, Invitrogen,
Molecular Probes, Carlsbad, CA) at room temperature for
1 h. After blocking, sections were incubated for 1 h
with a primary antibody against IL-17A (eBio64Cap17,
eBiosciences, San Diego, CA). All incubations were
performed at room temperature and between incubations
sections were washed with 1% blocking reagent. Primary
antibody was detected by incubation for 1 h with
biotinylated rabbit anti-mouse IgG (DAKO, Glostrup,
Denmark) and streptavidin-HRP (TSA HRP kit, Invitro-
gen) for 30 min, both diluted in 1% blocking reagent.
Sections were incubated for 10 min with tyramide-biotin
dissolved in amplification buffer (TSA HRP kit, Invi-
trogen) containing 0.15% H2O2. Next, sections were
again incubated for 30 min with streptavidin-HRP. To
reveal peroxidase activity, sections were incubated with
AEC (3-amino-9-ethylcarbazole, Sigma) substrate for
10 min resulting in a bright red precipitate. Sections were
counterstained with hematoxylin and embedded with
glycerol-gelatin. In control stainings in which the first
antibody was omitted or using an isotype control, no
immunopositive cells could be detected. For the lymph
nodes, the number of IL-17A producing cells is the mean
of the number of IL-17A-positive cells of three non-
adjacent sections.
Analysis of T cell reactivities
Ex vivo T cell responses against different antigens were
analyzed as described previously (Brok et al. 2000).
Briefly, PBMC were isolated by density gradient centri-
fugation over lymphocyte separation medium (Axis-
Shield PoC AS, Oslo, Norway). Mononuclear cell
(MNC) suspensions were prepared from aseptically
removed spleen and ALN. Cells were cultured in
triplicate for detection of proliferative responses towards
rhMOG and a panel of MOG peptides. All antigens were
tested at 5 μg/ml. After 48 h of culture, 0.5 μCi/well of
tritiated thymidine (
3H-Thy) was added and incorporation
of radiolabel was determineda f t e r1 8hu s i n gam a t r i x
9600 β-counter (Packard 9600; Packard Instrument
Company, Meriden, CT). Results are expressed as the
mean stimulation index (SI), which is defined as
the counts per minute (cpm) of stimulated cells divided
by the cpm of unstimulated cells. SI values above 2.0
were considered to be relevant.
The phenotype of proliferating cells was determined as
described previously (Kap et al. 2008). Briefly, 4×10
6
viable MNC from ALN or spleen were suspended in 1 ml
PBS and incubated for 7 min at room temperature with
CFSE (final concentration 1.5 μM; Fluka, Deisenhofen,
Germany). Labeled MNC were cultured for 7 days with
rhMOG or MOG peptides. For flow cytometric analysis
we used the following commercially available labeled
monoclonal antibodies directed against human CD
markers: Alexa Fluor 700-labeled anti-CD3 (BD
Biosciences), APC-labeled anti-CD4 (DAKO, Glostrup,
Denmark), biotinylated anti-CD8 (Serotec, Düsseldorf,
Germany), and streptavidin PerCP (BD Biosciences).
Flow cytometric analysis was performed on a FACSort
using FACSDiva software (BD Biosciences).
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Log-rank test, one-way ANOVA, and student's t test were
performed to statistically analyze the results. Results were
considered statistically different at p<0.05.
Results
Plasma levels of anti-IL-17A mAb
in rhMOG-immunized monkeys
The marmosets included in the study were randomly
assigned to three treatment groups. The control group
(n=8) received 1 ml/kg PBS and the two treatment groups
received anti-IL-17A mAb at 3 mg/ml/kg (n=8) or 30 mg/
ml/kg (n=7). The test substances were subcutaneously
administered once per week starting 1 day before immuni-
zation. Plasma levels of the anti-IL-17A mAb were
determined 7 days after each administration (Fig. 1). As
expected, plasma concentrations of the antibody in the
3 mg/kg antibody dose group were about tenfold lower
compared with the 30 mg/kg antibody dose group. In two
animals (M04099 and M03144) of the 3 mg/kg antibody
dose group plasma antibody trough levels, measured 1 week
after administration, were remarkably low, i.e., below 1 μg/ml
at psd 34, while these were above 1 μg/ml in all the other
monkeys of this group. In the 30 mg/kg antibody dose
animals, the plasma levels of the test substance were above
10 μg/ml from psd 6 throughout the experiment.
Clinical signs after anti-IL-17A mAb treatment
EAE was induced by a single immunization with rhMOG
emulsified in CFA. The course of clinical signs in
individual animals is depicted in Fig. 2. Solid lines
represent clinical scores and dotted lines represent percent-
age body weight loss, serving as a surrogate disease marker
in this model. The figure shows a similar disease course in
the monkeys that developed full-blown clinical EAE. Three
monkeys from the 3 mg/kg antibody dose group and one
monkey in the 30 mg/kg antibody dose group did not reach
the stage of hind-limb paralysis (score 3) within the pre-
determined observation period of 113 days psd. In the
3 mg/kg antibody dose group one monkey (M05020) did
not develop any signs of EAE within the pre-defined
observation period. A second monkey of this group
(M9913) reached EAE score 2 around psd 85, remitted
and developed a second episode of score 2 EAE which
remained present until the end of the observation period
(psd 106). Two monkeys (M04008 and M05004) had to be
sacrificed for ethical reasons with score 2 EAE due to
serious body weight loss. It is noteworthy that the two
monkeys with the lowest anti-IL-17A antibody plasma
levels at day 34 (M03144 and M04099) were amongst the
first monkeys to be sacrificed.
The EAE progression rate to overt neurological deficit
was defined as the time interval between the day of
rhMOG/CFA inoculation (psd 0) and the first day that
clinical score 2 was observed. At the level of this parameter
we observed a delayed EAE progression in the 3 mg/kg
antibody dose group (mean psd, 69.3; range, 48–113)
compared with the placebo group (mean psd, 57.1; range,
39–91) and the 30 mg/kg antibody dose group (mean psd,
60.0; range, 51–69). It is noteworthy that the variation
between animals of this parameter was much lower in the
30 mg/kg antibody dose group (18 days) than in the
placebo group (52 days) and the 3 mg/kg antibody dose
group (>65 days).
The disease progression from EAE score 2 (ataxia) to the
ethical end-points at score 3.0 (paraplegia) or excessive
body weight loss (>20%) was more rapid in placebo group
Fig. 1 Plasma levels of anti-human IL-17A mAb were sustained
during the study. Once a week, animals received a subcutaneous
injection with 1 ml/kg PBS (not shown), 3 mg/kg anti-IL-17A mAb
(left graph), or 30 mg/kg anti-IL-17A mAb (right graph) starting 1 day
before immunization. Plasma was collected from venous blood at
several time points during the study and anti-IL-17A mAb levels in
plasma were determined by ELISA. The y-axis have log scales. As
expected, the anti-IL-17A mAb plasma levels in the control animals
were throughout the experiment similar to the value on post-
sensitization day 0 of the treated animals (not shown). M04099 and
M03144 of the low antibody dose group were not able to sustain a
trough level of the antibody above 1 μg/ml
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346 J Neuroimmune Pharmacol (2011) 6:341–353monkeys (mean, 10.8 days; range, 3–20) than in monkeys
from the 3 mg/kg antibody (mean, 12.9; range, 5–28) and
30 mg/kg antibody (mean, 13.7; range, 6–31) dose group.
Statistical evaluation of both disease phases (score, 0–2 and
score, 2 to >2) was done by survival analysis, but no
significant differences were found (Fig. 3).
In summary, these data show a moderate inhibitory effect
of the antibody treatment on the EAE course, although
differences between the groups did not reach statistical
significance.
Effect of anti-IL-17A mAb on white matter lesion load
Prior to sectioning for histological examination, post-
mortem T2-weighted MR images were made of the
formalin-fixed cerebral hemispheres to visualize and
quantitate the total lesion load. The analyzed parameters
were lesion volume, T2,a n dM T Rv a l u e so fw h i t em a t t e r
lesions. In fixed brains, an increased T2 signal reflects
demyelination, while a reduction of MTR values correlates
well with the intensity of macrophage infiltration (Blezer
et al. 2007).
Significant differences were not observed between the
three groups (Table 1). In the analyzed hemispheres of two
animals of the control group cerebral white matter lesions
were absent. White matter lesion volumes were slightly
increased in the 30 mg/kg antibody dose group compared
with the placebo group. Especially monkey M05004 had
clinical score 2 for a long time, which might explain the
high lesion load. The lesions in the 3 and 30 mg/kg
antibody dose group had a slightly higher T2 and lower
MTR value compared with placebo (Table 1).
These results were confirmed by the quantitative
immunohistochemistry data (Table 1). Both inflammation
and demyelination were moderately increased, although not
significant, in the two antibody-treated groups compared
with the placebo group.
For the correct interpretation of these data it is pertinent to
emphasize that lesion formation in this model starts well
before neurological deficits can be observed. Moreover, most
animals were killed at the stage of clinically evident EAE,
which occurred at different time intervals after immunization.
It may therefore not be surprising that major effects of the
antibody treatment on the CNS pathology were not observed,
neither in positive nor in negative direction.
IL-17A expression in the brain and lymphoid organs
To assess the effect of anti-IL-17A mAb treatment on in
situ expression of IL-17A, cryosectioned brains and
lymphoidorganswere examinedwith immunohistochemistry.
In the brains of control and anti-IL-17A mAb-treated animals
IL-17A-positive cells were found in the perivascular space or
in the vicinity of blood vessels (Fig. 4a). No differences were
observed between placebo and anti-IL-17A mAb-treated
animals.
IL-17A-producing cells in secondary lymphoid organs
were mainly found in the red pulp of the spleen and in the
medulla of the lymph nodes. We observed a trend towards
higher numbers of IL-17A producing cells in the spleen of
animalsdosed with3 mg/kg anti-IL-17A mAbcomparedwith
animals that had received placebo or 30 mg/kg antibody, but
differences were not significant (Fig. 4a–b). By contrast, we
detected lower numbers of IL-17A producing cells in the
ALN and ILN, which drain the immunization sites, and the
brain-draining CLN, in both treatment groups compared
with the placebo group (Fig. 4a–b). Taken together, these
Fig. 2 Clinical score and body weight loss of rhMOG-immunized
marmosets. Shown are the clinical score (solid line, right y-axis) and
the body weight change in percentages compared with day 0 (dotted
line, left y-axis) of the placebo group (left graphs), the low dose group
(middle graphs), and the high-dose group (right graphs). Numbers in
the figure represent the time points (psd) when neurological signs
(score ≥2) were first observed and the day of sacrifice

Fig. 3 Survival curves. Survival time to score 2 (a) and survival time
to day of sacrifice (b) are shown. p Values indicated in the graph are
the results of comparing three groups. Comparing the survival to the
day of sacrifice of the control group versus only the 3 mg/kg group
resulted in a p value of 0.1610. When two animals of the 3 mg/kg
group with low anti-IL-17A mAb plasma levels (M04099 and
M03144) are included in the control group instead of the 3 mg/kg
group, the p value is 0.0428. According to the Bonferroni correction
this is not significant, but it is highly suggestive for a delay in disease
progression
J Neuroimmune Pharmacol (2011) 6:341–353 347data suggest that the antibody treatment caused altered
distribution of IL-17A producing cells over the different
lymphoid compartments.
Effect of anti-IL-17A mAb on T cell proliferation
Cellular immune parameters of the three groups were
examined to underpin the observed in vivo effects of the
IL-17A mAb. To this end, PBMC and MNC of spleen and
ALN were tested for proliferation against rhMOG and a
panel of 23-mer overlapping MOG peptides.
Similar to previous studies (Kap et al. 2008), prolifera-
tion of PBMC during the disease course and at necropsy
was low and remained confined to the immunizing rhMOG
protein and a few peptides, i.e. MOG14–36, MOG24–46, and
MOG34–56 (Fig. 5). No clear differences were observed
between the three groups.
More robust proliferative responses were observed in the
lymphoid organs, especially in the ALN and spleen. Figure 5
shows that in most animals the highest proliferative response
was against rhMOG followed by peptides MOG14–36 and
MOG24–46. MNC from the ALN of the anti-IL-17A mAb-
treated groups displayed a lower proliferative response
against rhMOG and MOG peptides than MNC from ALN
of the placebo group (Fig. 5). No differences between the
three groups were observed in the spleen (Fig. 5).
Next, we analyzed the phenotype of the rhMOG
responsive cells using the CFSE fluorescent dye dilution
Table 1 White matter lesion parameters
Animal WM lesions assessed by MRI Histology
Volume (mm3) T2 (ms) MTR # Inflammatory lesions/cm2 # Demyelinating lesions/cm2 Demyelination %
Control
M0176 87 28.0 31.3 16 4.7 1.5
M03115 597 24.0 32.0 20 9.2 1.5
M04009 150 29.7 30.3 15 3.7 0.8
M04098 0 –– 1 0.2 0
M04109 163 26.0 32.1 19 5.3 1.6
M05011 2 23.2 35.9 3 1.0 0.1
M05014 0 –– 0 0.0 0
M05023 449 27.9 31.2 60 6.2 1.3
Mean 181 26.5 32.1 17 3.8 0.9
SEM 79 1.0 0.8 7.9 1.3 0.3
3 mg/kg
M03144 483 29.9 29.9 32 7.7 1.6
M04008 135 27.6 29.2 25 9.8 1.6
M04099 113 26.6 33.9 11 1.7 0.3
M04122 354 27.6 31.2 45 12.0 2.4
M05020 178 26.1 33.3 19 3.3 0.4
M05021 30 29.3 30.9 5 2.0 0.2
M05024 642 27.5 31.2 52 11.0 2
M9913 321 25.9 29.7 13 4.3 3.3
Mean 282 27.5 31.2 25 6.5 1.5
SEM 73 0.5 0.6 5.9 1.5 0.4
30 mg/kg
M03116 39 27.0 32.8 6 2.5 0.3
M03149 304 31.9 28.7 5 1.0 0.2
M03160 50 32.8 28.6 45 8.7 1.1
M04049 212 25.9 32.3 68 4.7 1.1
M04112 354 27.6 31.2 34 8.7 3
M05004 1261 25.8 29.7 52 8.8 3.4
M05039 715 27.1 31.5 18 3.2 0.7
Mean 419 28.3 30.7 33 5.4 1.4
SEM 165 1.1 0.6 9.1 1.3 0.5
348 J Neuroimmune Pharmacol (2011) 6:341–353Fig. 4 Differential expression
of IL-17A in the brain and
lymphoid organs. IL-17A
expression was detected by
immunohistochemistry. a (200×)
Representative examples of each
group for brain, spleen, and
axillary (ALN), inguinal (ILN),
and cervical (CLN) lymph
nodes. b IL-17A positive cells
per mm
2 (mean ± SEM). Only
one CLN of the control group
was analyzed. No IL-17A
producing cells were detected in
the ILN of the 30 mg/kg treated
group. Statistical differences
between the numbers of IL-17A
positive cells were analyzed by
One-way ANOVA. Results were
considered statistically different
at p<0.05. No statistical
differences were found between
the three groups
J Neuroimmune Pharmacol (2011) 6:341–353 349technique in combination with cell phenotyping for surface
markers. RhMOG responsive CD3
+CD4
+ and CD3
+CD8
+
cells with CFSE dye dilution were visualized by flow
cytometry. The percentages of CD3
+CD4
+ and CD3
+CD8
+
cells determined by fluorescent dye dilution did not differ
significantly between placebo and anti-IL-17A mAb-treated
groups (data not shown), suggesting that the treatment with
anti-IL-17A mAb did not cause a skewing of the CD4/CD8
ratio of rhMOG-specific T cells.
In conclusion, treatment with the anti-IL-17A antibody did
not exert an obvious effect on the quality or quantity of the
cellular autoimmune reactions. However, we like to empha-
sizeagainthattheanalyzedlymphoidorganswerecollectedat
different time intervals after the EAE induction, creating a
possible bias in the data.
Discussion
Key pathogenic elements for EAE development in rhMOG-
immunized marmosets comprise CD40, IL-12, and IL-23 ('t
Hart et al. 2005a; Boon et al. 2001; Brok et al. 2002;
Laman et al. 2002). We have shown that an antibody
against the shared p40 subunit of IL-12 and IL-23 caused
profound suppression of disease symptoms when dosed
from disease induction. One possible mechanism of action
could have been a reduction in IL-17A that is one of the
downstream cytokines from IL-23. However, the modest
effect of an anti-IL-17A antibody in the current study
indicates that a reduction in IL-17A does not account for
the activity of IL-12 p40 antibody and that other cytokines,
perhaps IL-12 directly or other cytokines downstream of
IL-12 and/or IL-23, are more important in the induction
phase of this non-relapsing model.
The results of the current study demonstrate that
prophylactic treatment with an anti-IL-17A mAb induced
only a moderate extension of the disease-free time interval
after EAE induction. Furthermore, immune parameters of
the disease, such as T cell proliferation against rhMOG or
MOG peptides was only somewhat reduced, whereas also a
marginal aggravation of CNS pathology was observed.
However, the variations were all within the normal range of
variation in this outbred model and may also be attributable
to the longer survival. Using immunohistochemistry only a
few IL-17A-positive cells could be detected in the brains of
placebo and treated monkeys, but no significant differences
Fig. 5 T cell responses after anti-IL-17A mAb treatment. PBMC and
mononuclear cells isolated from the axillary lymph node and spleen at
necropsy were tested for proliferation against rhMOG and MOG
peptides. The stimulation index (SI) was calculated by dividing the
counts per minute (cpm) of stimulated wells by cpm of unstimulated
wells. The stimulation index is divided into groups with different
shading as indicated in the figure
350 J Neuroimmune Pharmacol (2011) 6:341–353between groups were observed. The data show a trend
towards increased numbers of IL-17A-positive cells in the
spleen in the 3 mg/kg group and a decreased number in the
axillary and inguinal lymph nodes of both groups compared
with placebo animals (not significant). The higher number
of Th17 cells in the spleen of monkeys that have been
treated with anti-IL-17A antibody compared with placebo
monkeys may be explained by feedback regulation. The
observation that IL-17A receptor deficient mice produce
more IL-17A (Smith et al. 2008) indicates that IL-17A
production may be regulated by a negative feedback loop.
In conclusion, the current results fail to show a robust effect
of the anti-IL-17A mAb treatment on the EAE course in
rhMOG/CFA-immunized marmosets.
The moderate protection against EAE induction is in
agreement with data reported by some groups in mouse
EAE models. Also in IL-17A
−/− mice (Komiyama et al.
2006), in mice treated with anti-IL-17A mAb (Chen et al.
2006; Hofstetter et al. 2005; Langrish et al. 2005), and in
mice vaccinated against IL-17A (Rohn et al. 2006) only
moderately delayed onset of clinical signs has been
observed. However, other groups have demonstrated more
robust effects of IL-17A on the EAE course in mice.
Examples are by vaccination with IL-17A-OVA complexes
that induce IL-17A blocking antibodies (Uyttenhove and
Van Snick 2006) or adoptive transfer of IL-17
+ and IL-17
−
T cells (Jager et al. 2009; Komiyama et al. 2006; Langrish
et al. 2005). Furthermore, in the chronic-relapsing EAE
model in Biozzi ABH mice, prophylactic dosing with an
anti-IL-17A antibody produced a small delay in onset of the
acute phase of disease, whereas treatment with the antibody
started after the acute phase or during the secondary-
progressive phase was very efficacious, and could even
reverse the chronic motor disability (Smith, unpublished
observations). Other groups suggested that Th17 are not
pathogenic at all (Haak et al. 2009) or that besides Th17
cells, Th1 cells are also essential in EAE (Kroenke et al.
2008; Lees et al. 2008; O'Connor et al. 2008).
How can it be explained that IL-17A neutralization does
not fully protect against EAE in the rhMOG-induced
marmoset model? One possible explanation is the high
complexity of the model. Unraveling of the pathogenic
mechanism showed that the disease is initiated by MOG24–
36-specific Th1 cells, which induce small inflammatory
lesions (Brok et al. 2000). The moderate inflammatory
injury caused by Th1 cells can be dramatically amplified by
antibodies against conformational epitopes of MOG (Gen-
ain et al. 1995), which are clearly produced in the rhMOG
model. Another subset of highly reactive T cells with
natural killer-cytotoxic T-lymphocyte characteristics and
specific for MOG34–56 becomes involved at a later stage in
the disease (Kap et al. 2008). Our previously reported
studies in marmoset EAE models induced with MOG34–56
in CFA (Kap et al. 2008) or IFA (Jagessar et al. 2010)
demonstrated that the same clinical and pathological end-
points can be reached via different immunopathogenic
routes. It can thus be envisaged that after neutralization of
IL-17A in the complex rhMOG/CFA-induced model other
pathogenic mechanisms, such as Th1 cells, may come into
play. It could also be possible that Th1 and Th17 cells act in
different phases of the disease. In the previously reported
study in the rhMOG marmoset model it was observed that
Th1 cells specific for MOG24–36 are engaged in EAE
induction, whereas MOG34–56-specific T cells, which pro-
duce mainly IL-17A, mediate disease progression (Jagessar
et al. 2010; Kap et al. 2008). This suggests that, consistent
with the results in the Biozzi ABH mouse model, neutral-
izing IL-17A in a later phase of the disease is more effective.
Yet, another possible explanation is that IL-17A,
although being the signature cytokine of Th17 cells, is not
the dominant pathogenic factor produced by Th17 cells.
This explanation is supported by data in mice. IL-12/IL-
23p40
−/− mice are completely resistant to EAE, whereas
only clinical scores and not the disease incidence is reduced
in IL-17
−/− mice (Becher et al. 2002; Cua et al. 2003; Gran
et al. 2002; Komiyama et al. 2006). Moreover, treatment of
mice with anti-IL-23 antibody prevented either EAE
induction or relapse, in contrast to the anti-IL-17A antibody
treatment that blocked relapse, but had a smaller effect on
the induction phase (Chen et al. 2006). This may suggest
that other Th17 cytokines induced by IL-23 may be
pathogenetically more relevant than IL-17A in the induc-
tion phase, such as IL-21 or IL-22 (reviewed in (Fouser et
al. 2008)). In addition, Chen et al. suggested that IL-23 may
also directly activate macrophages to produce inflammatory
cytokines, such as IL-6, IL-1, and TNF-α, which may cause
inflammation and demyelination even when IL-17A is
neutralized (Chen et al. 2006).
Is there a place for an IL-17A neutralizing antibody in
the treatment of MS? Axtell et al. reported that on the
basis of clinical response to IFN-β two groups may be
distinguished in the MS patient population. Responsive-
ness to IFN-β treatment requires a Th1 cytokine profile,
whereas cases with a Th17 dominated cytokine profile
are non-responders to IFN-β treatment (Axtell et al.
2010). It is tempting to speculate on the basis of these and
our data that non-responder cases to IFN-β treatment in
the MS population may benefit from treatment with IL-
17A antibody. The ideal study design to obtain proof-of-
principle may be a parallel effectivity analysis in the
marmoset EAE model, where in one sibling of a chimeric
twin EAE is induced with MOG34–56 in CFA, which is a
Th1 prone model (Jagessar et al. 2010; Kap et al. 2008)
and in the other twin sibling with MOG34–56 in IFA, which
is a more Th17 prone disease (Jagessar et al. 2010;K a p
et al. 2008).
J Neuroimmune Pharmacol (2011) 6:341–353 351In summary, we found that treatment with anti-IL-17A
antibody induces a moderate delay of clinical EAE in
marmosets, but that EAE is not completely abrogated. This
suggests a pathogenic role for IL-17A in the marmoset EAE
model and maybe in MS, but IL-17A may not be the only
key pathogenic cytokine.
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